Doctors at the National Institutes of Health (NIH) are conducting a research study to determine the viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with severe aplastic anemia (SAA).
Study design:
- Patients with SAA will be treated with cyclosporine and eltrombopag either before arrival to the NIH or at the NIH while work up is being completed
- When the treatment is initiated remotely, it will be under the supervision of investigators at the National Heart, Lung, and Blood Institute (NHLBI)
- All patients will receive standard treatment with cyclosporine, eltrombopag, and
- Horse Anti-thymocyte-Globulin (h-ATG) at the NIH-Clinical Center, unless there is complete count recovery with oral therapy
Who can participate:
- Patients ages 3 and older with SAA who:
- have not received previous ATG-based immunosuppressive treatment and lack a suitable matched sibling marrow donor; OR
- are not allogeneic transplantation candidates due to patient choice, advanced age, or infeasibility of transplantation
To learn more, call:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
(TTY users dial 7-1-1)
Email: ccopr@nih.gov
Or go online:
http://bit.ly/3mxl7gY
Refer to study # 20-H-0033
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Heart, Lung and Blood Institute (NHLBI)